Name of the institute: Université Paris Descartes, Faculté de Pharmacie
Name of the team: NF-kB, Differentiation and Cancer
Name of the leader: Catherine Thieblemont M.D., Ph.D./Véronique Baud, Ph.D.
Location: Paris, France.
Abstract of the project: Diffuse large B-cell lymphoma (DLBCL) is the most common aggressive non-Hodgkin lymphoma. Up to 40% of DLBCL patients will ultimately relapse or progress and die, highlighting the crucial need for novel therapeutic strategies. Remarkably, we have recently demonstrated that metabolic inhibition is of great clinical benefit for refractory/relapsed DLBCL patients. Further, growing understanding of the complex dialog between tumor cells and their microenvironment contributed to the development of immune checkpoint inhibitors. The proposed PhD program aims at studying the interplay between anti-metabolic drugs and (i) immune checkpoints (e.g. PDL-1, CTLA-4) and (ii) NF-kB activation, a master control of immune response, in aggressive relapsed/refractory DLBCL to improve clinical efficacy. The project will be conducted in DLBCL patient samples, cell lines using co-culture systems, and in vivo animal models.
As part of our MSCA-ESR training on complementary skills we got to leave the wet lab to explore what happens on the other side of the bench and to learn what it means to be a scientific editor. This is our story.
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under the Marie Skłodowska-Curie grant agreement No 766214.
Bellvitge Biomedical
Research Institute (IDIBELL)
Hospital Duran i Reynals, 3a planta
Gran Via de l’Hospitalet, 199
08908 L’Hospitalet del Llobregat
Barcelona, Spain
